doi: 10.1161/01.RES.0000264509.36234.51
© 2007 American Heart Association, Inc.
Reviews |
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
From the Department of Cardiovascular Medicine, Cleveland Clinic, Ohio.
Correspondence to Deepak L. Bhatt, MD, Associate Director, Cleveland Clinic Cardiovascular Coordinating Center, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195. E-mail bhattd{at}ccf.org
This Review is part of a thematic series on Mechanisms, Models, and In Vivo Imaging of Thrombus Formation, which includes the following articles:
Activation of Platelet Function Through G Protein–Coupled Receptors
Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease
In Vivo Thrombus Formation in Murine Models
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Platelet Adhesion
Bernhard Nieswandt and Ulrich Walter Guest Editors
The platelet, once thought to be solely involved in clot formation, is now known to be a key mediator in various others processes such as inflammation, thrombosis, and atherosclerosis. Supported by the wealth of evidence from clinical trials demonstrating their benefits in patient outcomes, antiplatelet agents have become paramount in the prevention and management of various diseases involving the cardiovascular, cerebrovascular, and peripheral arterial systems. Despite being among the most widely used and studied classes of medical therapies, new discoveries regarding important clinical aspects and properties of these agents continue to be made. As our understanding of platelet biology expands, more effective and safer novel therapies continue to be developed. The use of more refined agents in conjunction with a better understanding of their effects will further the ability to provide more optimized care on an individual basis.
Key Words: antiplatelet therapy • thrombosis • platelets • atherosclerosis • cardiovascular disease
This article has been cited by other articles:
 |
|
 |
|
  J. S. Berger, D. L. Bhatt, C. P. Cannon, Z. Chen, L. Jiang, J. B. Jones, S. R. Mehta, M. S. Sabatine, S. R. Steinhubl, E. J. Topol, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1935 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt, A. M. Lincoff, C. M. Gibson, G. W. Stone, S. McNulty, G. Montalescot, N. S. Kleiman, S. G. Goodman, H. D. White, K. W. Mahaffey, et al. Intravenous Platelet Blockade with Cangrelor during PCI N. Engl. J. Med., November 15, 2009; (2009) NEJMoa0908629v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt Prasugrel in Clinical Practice N. Engl. J. Med., September 3, 2009; 361(10): 940 - 942. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt Tailoring Antiplatelet Therapy Based on Pharmacogenomics: How Well Do the Data Fit? JAMA, August 26, 2009; 302(8): 896 - 897. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rivera, M. L. Lozano, L. Navarro-Nunez, and V. Vicente Platelet receptors and signaling in the dynamics of thrombus formation Haematologica, May 1, 2009; 94(5): 700 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mahmud and A. Prasad Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 846 - 848. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mehta, P. Gao, D. L. Bhatt, R. A. Harrington, S. Skerjanec, and J. H. Ware Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies Circulation, February 3, 2009; 119(4): 597 - 605. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell Antiplatelet Agents in the Perioperative Period Arch Surg, January 1, 2009; 144(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt Resisting the Temptation to Oversimplify Antiplatelet Resistance J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 660 - 662. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Talelli and R. J. Greenwood Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 387 - 405. [Abstract] [PDF]
|
|
|
|
|
|
D. L. Bhatt What Makes Platelets Angry: Diabetes, Fibrinogen, Obesity, and Impaired Response to Antiplatelet Therapy? J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1060 - 1061. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: II. Perioperative Considerations and Management Anesth. Analg., August 1, 2008; 107(2): 570 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pawlinski, M. Tencati, C. R. Hampton, D. Spring, T. H. Pohlman, E. D. Verrier, T. Shishido, T. A. Bullard, L. M. Casey, J.-i. Abe, et al. Response to Letter Regarding Article, "Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy" Circulation, June 17, 2008; 117(24): e496 - e496. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. BAKHRU and D. L. BHATT INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Manrique, G. Lastra, J. Palmer, M. Gardner, and J. R. Sowers Review: Aspirin and Diabetes Mellitus: revisiting an old player Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 37 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Gachet and B. Aleil Testing antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A28 - A34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis N. Engl. J. Med., November 15, 2007; 357(20): 2078 - 2081. [Full Text] [PDF]
|
|